With the use of anti-inflammatory drugs constituting the standard of care for treating rhinosinusitis, Lyra Therapeutics sees an opportunity.
Whatever treatments are out there for the disease in which cavities around the nasal passages are inflamed, they leave room for improvement.
“We focused on chronic rhinosinusitis because it’s an area that has been ignored,” Lyra CEO Maria Palasis told Drug Delivery Business News. “It’s been called an unrecognized epidemic. It’s a disease where there, there just aren’t a lot of treatments.”
Watertown, Mass.-based Lyra has taken the initiative with its XTreo platform and the LYR-210 therapeutic.